> The revision in the ratings assigned to the bank facilities of IOL Chemicals and Pharmaceuticals Limited (IOL) takes into account its improved financial risk profile in FY21 (refers to period from April 01 to March 31) marked by healthy growth in the profitability and improved capital structure. Further, the revision is also on account its strong liquidity and strengthening of debt service metrics.
IOLCP has received approval of Korean Ministry of Food and Drug Safety for Company’s API products 'Ibuprofen and ‘Fenofibrate’. This approval re-establishes the Company’s efforts to keep the highest quality standards and to increase presence in the regulated markets. This will naturally strengthen Company’s presence in South Korean market.
Intrinsic value as per screener is 1443. One of the major reason as everyone know for trading at such low valuation is over concentration on Ibuprofen and price of Ibuprofen remaining stagnant over last couple of months, IOL will continue to trade at forward multiple of 8-9 times only. If the market price needs to move to close to the intrinsic level, management needs to come out with a concrete plan of entering into high value products and more specifically specialty chem.
When asked in one of the earnings call, management did mention that their focus would be on manufacturing APIs in high volume, gradually improve the process and make these new molecules more profitable. Example, Gabapentin is facing severe competition still IOLCP went ahead to introduce this API in their portfolio.
Company is debt free and has decent amount of cash. IMO, IOLCP is not under pressure to hasten large number of successful molecules to overtake Brufin revenue
I am a long term investor but bit worried seeing decline from last 4 qtrs.
There was many things discussed in the last con call including various factor affecting price.
I am putting my notes here.
22 Nov con call
the company had a muted growth during the quarter.
The total revenue for the quarter increased by 2% to Rs.548 as compared to Rs.538 Crores in Q1 FY2021.
In Q2 of Financial year 2022 the EBITDA was at Rs.63
Depreciation for the quarter was Rs.11 Crores and Rs.21 Crores for first half 2022
Profit after tax for Q2 of financial year 2022 stood at Rs.31 Crores
there was some increase in raw material pricing, some of that we had been successfully able to pass on to customers and that will be reflected in the coming quarters
for some other areas, we are seeing a correction in the raw material pricing already in this quarter
So we do expect that this is a temporary blip that will correct itself within the next one or two quarters
The reason it is a temporary blip is that even if the raw material prices continue to be high we will be able to successfully pass along that cost increase to customers
we are expecting certainly maybe 330 Crores to 350 Crores kind of topline coming into the non-ibuprofen business for us this year and next year onwards we are very confident that you will see substantial jump in that figure.
Ibuprofen: peak capacity we believe that we can go through at least 85%-90% utilization and we have done that in the past
Ibuprofen: $11 to $12
Ibuprofen worlwide demand is 35000 and 40000 tons had contracted to maybe around 30000 tons and within the next two quarters it will be back to 35000 levels
Where do we see ourselves three years down the line. Because I remember like three quarters back when we had discussion with the outgoing CEO, he did mention that we will grow around 18% to 20% so, maybe by FY2024 we are looking at somewhere around 2800 - 2900 are we on track of is there a change if you can let know? Ans: We are on track I think 15% to 18% is a reasonable number for us and we will certainly in the next two to three years be achieving or exceeding both numbers.
The only capex that we have ongoing is the delayed project Unit No.9 that is a multiproduct facility that should be up and ready by the end of this quarter and that is the only one
Disc: i will wait for few more qtrs before taking any decision.
The irony in this statement of the company is when there is a product facing severe competition, it still tries to make it and in a more profitable way. On the other hand severe competition would reduce the margins by cutting the price.
“high volume” and “improving the process” can be copied by the competitors too.
IOLCP is not under pressure to hasten large number of successful molecules to overtake Brufin revenue
IOL has been very profitable only in the last three years. @reacharjunr is right when he says that the management should enter into high value product but it would require the necessary skill set.
IOL Chemicals incorporates a new subsidiary to focus on Pharmaceuticals and Chemicals business
IOL Life Sciences Limited incorporated as wholly-owned subsidiary of the Company on
20" June 2022.
Authorised Share Capital: Rs. 10,00,000
Paid-up Share Capital: Rs. 10,00,000
Size/Turnover: Not applicable
(yet to commence business operations)